Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme
|Company Announcement |
Copenhagen, 19 Sep 2022
Transactions in connection with share buy-back programme
On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme.
Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023.
The following transactions have been executed from 12 September to 16 September 2022:
|Number of shares||Average |
purchase price, DKK
|Transaction value, DKK|
|Accumulated, last announcement||2,915,985||397,342,580|
|Total, 12 September - 16 September 2022||178,686||109.81||19,622,208|
|Bought from CAF, 16 September 2022*||79,744||109.81||8,757,000|
|Bought from CWO, 16 September 2022*||36,918||109.81||4,054,110|
|Accumulated under the programme||3,211,333||429,775,898|
*According to separate agreements as from 20 May 2022 Chr. Augustinus Fabrikker Aktieselskab (CAF) participates on a 27.0% pro-rata basis and C.W.Obel A/S (CWO) participates on a 12.5% pro-rata basis to the shares purchased in the share buy-back programme.
A detailed overview of transactions during the period 12 September – 16 September 2022 is attached to this announcement.
Following the above transactions Scandinavian Tobacco Group A/S owns a total of 3,657,395 treasury shares, corresponding to 3.93% of the total share capital.
For further information, please contact:
Torben Sand, Head of Investor Relations,
phone: +45 5084 7222 or email@example.com
- Company Announcement no 57 2022
- PUBLIC_SBB_SCANDINAVIAN TOBACCO GROUP
- PDMR notification CWO 16 Sep 2022
- PDMR notification CAF 16 Sep 2022
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Phoenix Software Delivers a Faster JES3plus® with V1R227.9.2022 13:00:00 CEST | Press release
Phoenix Software releases updates to its product line in September 2022 EL SEGUNDO, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Phoenix Software International, Inc., today announced its intention to make JES3plus V1R2, a derivative work based on IBM’s z/OS® JES3, generally available effective September 30, 2022. This release provides new functionality and integrates continuous delivery items made available over the past twelve months. Thanks to Phoenix’s JES3plus Customer Advisory Council, organizations that migrate to JES3plus can reap the benefits of new features that were ranked in terms of providing true business value to their fellow customers. JES3plus V1R2 Functional Highlights: Parallel SPOOL I/O – Takes full advantage of the Parallel Access Volumes technology supported by modern mainframe DASD through support for up to eight STARTIO channel programs running concurrently for a single SPOOL extent. This is a major improvement over the traditional JES3 approach of allowing only on
Norsk Hydro: Invitation - Hydro's third quarter 2022 results27.9.2022 13:00:00 CEST | Press release
Hydro's third quarter 2022 results will be released at 07:00 CEST (01:00 AM EST, 06:00 GMT), on Tuesday, October 25, 2022. The quarterly report and presentation slides will be available on hydro.com at the same time. Presentation in Oslo Hydro will host an in-person presentation and Q&A, in English, at the Felix Conference Centre at Bryggetorget 3, Oslo, at 08:30 CEST on Tuesday, October 25, 2022. The presentation, by President and CEO Hilde Merete Aasheim and CFO Pål Kildemo, can also be seen on the webcast. To attend the presentation in Oslo, please register your details via this link. There will also be a separate virtual Q&A session at 11:00 CEST. Please register your details using this link to join the conference call. Once registered, you will receive an email containing your dial in number(s) and PINs. Investor contact: Line Haugetraa +4741406376 firstname.lastname@example.org
Norsk Hydro: Presentasjon av Hydros resultat for tredje kvartal 202227.9.2022 13:00:00 CEST | Pressemelding
Hydros resultat for tredje kvartal 2022 blir offentliggjort tirsdag 25. oktober 2022 kl. 07.00 CEST (01:00 AM EST, 06:00 GMT). Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på hydro.com. Presentasjon i Oslo Det blir holdt fysisk presentasjon og Q&A ved Felix Konferansesenter på Bryggetorget 3, Oslo, samme dag, kl. 08.30 CEST. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for økonomi og finans Pål Kildemo. Hele presentasjonen kan følges direkte på webcast. For å delta på presentasjonen i Oslo, vennligst registrer dine detaljer via denne lenken. Det vil være også være en separat digital Q&A telefonkonferanse klokken 11:00 CEST. Vennligst benytt denne lenken for å registrere deg til telefonkonferansen. Etter registrering vil du motta en epost med telefonnummer og deltakerkode. Investorkontakt: Line Haugetraa +4741406376 email@example.com
Lytho Appoints Geert Bruinink to Lead Operations in Europe27.9.2022 10:00:00 CEST | Press release
Seasoned Executive Brings a Mix of General Management and Sales Leadership as the Company Expands Reach in Europe for its Creative Workflow and Digital Asset Management (DAM) Software AMSTERDAM, the Netherlands and RALEIGH, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Lytho, a creative operations platform providing creative workflow and digital asset management (DAM) tools to brand and creative teams, today announced it has hired Geert Bruinink as its Country Manager based in The Netherlands. He will report to Lytho CEO Douglas Thede and have overall responsibility for the company’s European sales and operations. “Geert brings a proven track record of general management and sales leadership skills to Lytho as we extend our presence in Europe,” said Thede. “We’ve seen strong demand for our software because in-house creative teams have grown, and our tools reduce the natural complexity that comes with that growth. We’re thrilled to welcome Geert as a Lythonian and look forward to his contrib
Conagen unveils commercial production of high-purity non-GMO salidroside27.9.2022 10:00:00 CEST | Press release
Ideal for adaptogen supplement solutions and natural preservatives in food and beverages. Bedford, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Conagen announced the commercialization of its 99% high-purity salidroside made by bioconversion technology, an active ingredient from the herbal plant Rhodiola rosea (golden root). Its strong antioxidant properties as an adaptogen are associated with reducing inflammation, protecting against oxidative stress in cells, and providing relief from depression, fatigue, and stress. Salidroside has also been used to alleviate high altitude sickness. Unlike other salidroside products currently on the market, Conagen’s salidroside is non-GMO. Conagen leveraged its industry-leading bioconversion technology to produce clean, sustainable salidroside, identical to the compound naturally found in the Rhodiola rosea plant --- the same technology used to produce non-GMO Rebaudioside M, other steviol glycosides, and bitter blockers for sugar reduction solutions w